Contact us for more information

Stephen J. PettiStephen J. Petti, R.N., BSN, BBA, FAHA
Co-Founder and Chief Executive Officer

See expanded bio on Company Management page.

Email him at sjpetti@hibernaid.com

 

Laurence Katz, M.D.Laurence M. Katz, M.D.
Co-Founder and Chief Medical/Scientific Officer

See expanded bio on Company Management page.

Email him at lkatz@hibernaid.com

 

Ron Tribble, DMDRon Tribble, DMD
Senior Business Advisor

See expanded bio on Company Management page.

Email him at rtribble@hibernaid.com

 

Kathryn M. Martin, PharmDKathryn M. Martin, Pharm.D.
V.P. of Clinical Operations

Dr. Martin, VP of Clinical Operations, joined Hibernaid in July 2010. Kate has 25 years of experience in clinical trial management and regulatory affairs. She heads up the company's Regulatory Affairs effort, as well as medical writing and scientific communications. Dr. Martin holds a BS in Pharmacy from Northeastern University and a Pharm D from the University of Texas in Austin. She completed residency training in oncology pharmacy practice at the Audie Murphy VA Hospital and was among the first clinical pharmacists in the United States to become certified by the American Society of Health Systems Pharmacists. Kate has experience in a range of areas within pharmaceutical development, including medical writing, regulatory affairs, and IND/NDA/BLA development and filings. This experience includes interpreting clinical and statistical data, writing of clinical and regulatory documents, and development/execution of scientific communication plans. She has previously served as a consultant to Novartis, Amgen, Teva Pharmaceuticals, Wyeth Ayerst and Drais Pharma. She is the founder and president of Glenmere Research in Montebello NY, an independent contract firm specializing in medical writing and regulatory affairs.

Email her at kmmartin@hibernaid.com


Melissa BarronMelisa K. Barron, Ph.D.
Director, Chemistry, Manufacturing and Controls/Formulations Development

Melisa Barron joined Hibernaid in 2012 with over 20 years of industry experience as scientific contributor and management. She heads the Company's CMC and formulations development. Dr. Barron holds a B.S. degree in Chemistry and obtained her Ph.D. in Pharmaceutical Sciences at the University of Texas at Austin specializing in drug delivery of biologics and poorly soluble small molecule therapeutics. Dr. Barron has held key development team and leadership positions at Theravance and Affinium Pharmaceuticals responsible for managing technical consultants and contract manufacturing and research organizations to support non-clinical and Phase I/II/III development of novel, small molecule antibiotics. As senior scientist at Theravance, Dr. Barron was principal to the successful NDA submission and approval for marketing and commercialization of the new drug product, VIBATIV™ (Telavancin®) for Injection in September 2009. She is the author of many research articles in peer reviewed scientific journals and has delivered several presentations at scientific conferences in the US and abroad. Dr. Barron is owner of an independent contract consulting firm providing professional pharmaceutical development consulting services with expertise in drug delivery, manufacture of clinical trial materials and regulatory submissions. As a consultant Dr. Barron recently worked with Achaogen Inc. in development of the new drug product, plazomicin injection and assisted in preparation of the NDA submission in late 2017.

Email her at mkbarron@hibernaid.com


Samn RaffanielloSamn Raffaniello
VP, Administrative Systems and Support Services

See expanded bio on Company Management page.

Email her at samn@hibernaid.com